KESIMPTA (Novartis Pharmaceuticals Australia Pty Ltd)
Product name
KESIMPTA
Date registered
Evaluation commenced
Decision date
Approval time
189 (255 working days)
Active ingredients
ofatumumab
Registration type
EOI
Indication
KESIMPTA (solution for injection) is now also indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) to delay the progression of physical disability and reduce the frequency of relapse (refer to section 5.1).